Summary
Boston Scientific Corporation (BSX) announced on May 7, 2015, the pricing of a significant public offering of $1.85 billion in senior notes. This offering is structured into three tranches with varying maturity dates and interest rates: $600 million of 2.850% notes due 2020, $500 million of 3.375% notes due 2022, and $750 million of 3.850% notes due 2025. The offering is expected to close on May 12, 2015. The primary purpose of this debt issuance is to finance the acquisition of the American Medical Systems (AMS) urology portfolio. The net proceeds, combined with funds from a $750 million term loan facility, will be used to cover the purchase price, fees, and expenses associated with the AMS Portfolio Acquisition. Additionally, the company plans to use a portion of these proceeds to redeem outstanding notes maturing in November 2015 (5.500%) and June 2016 (6.400%), aiming to optimize its debt structure and reduce future interest obligations.
Key Highlights
- 1Announced pricing of a $1.85 billion senior notes offering on May 7, 2015.
- 2Offering comprises $600M (2.850% due 2020), $500M (3.375% due 2022), and $750M (3.850% due 2025) notes.
- 3Expected closing date for the offering is May 12, 2015.
- 4Proceeds will fund the acquisition of the American Medical Systems (AMS) urology portfolio.
- 5Debt offering is also intended to redeem existing notes due November 2015 and June 2016.
- 6Utilizing a $750 million five-year term loan facility in conjunction with the note offering.
- 7The filing includes a press release detailing the offering as Exhibit 99.1.